Small-cell lung cancer (SCLC) makes up 15% of all lung cancers diagnosed and is character-ized by its aggressive type. Although immune checkpoint blockade combining a programmed cell death ligand-1 (PD-L1) inhibitor atezolizumab with carboplatin and etoposide has proven to be effective, tumor cells finally acquire the ability to evade immunosurveillance. Previous results have shown that SCLC metastases and primary SCLC with acquired resistance develop loss of MHC-I surface expression and that MHC-II surface expression may be required for sufficient immune mediated killing. Thus, mechanisms of boosting MHC-I and MHC-II class expression on tumor cells need to be deciphered to enhance the antitumor immune response upon combined therapy regimens.
 

https://innere1.uk-koeln.de/forschung/arbeitsgruppen-labore/krebstherapie-und-molekulare-bildgebung/